Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis

Fig. 4

Silencing EDI3 in HCC1954 reduces formation of peritoneal metastasis in mice and improves survival. A Schematic illustration of the experimental plan. Luciferase-expressing HCC1954 shNEG and shEDI3 cells were induced with doxycycline for 72 h. EDI3 mRNA expression and corresponding Western blot showing reduced EDI3 expression in the HCC1954-luc shEDI3 cells at time of injection. Doxycycline-treated (induced) and non-treated (non-induced) cells were injected into the peritoneum of doxycycline pre-treated and untreated CD1 nude mice, respectively. Doxycycline was administered to the mice by a 625 mg/kg doxycycline containing diet (Ssniff) ad libitum. Luminescence signal was measured over ten weeks and the time of survival was recorded. Quantitative analysis of luminescence signal for B shEDI3 and C shNEG normalized to T0. D Corresponding representative luminescence images of mice. Survival of mice was observed for 15 weeks after intraperitoneal injection with E shEDI3 and F shNEG cells. Data in B and C represent seven mice per condition. Data in E and F represent 12 (shEDI3) or seven (shNEG) mice per condition. Box plots: horizontal line, median; box, 25th–75th percentiles; whiskers, min to max. Kaplan–Meier curves: p values were determined by log-rank test (*p < 0.05; **p < 0.01)

Back to article page